GlassScriptPhysician profile
Archana Shetty
NPI 1821091240
$1,417.60
in general payments reported to CMS, 2019-2025
23 companies · $657 in 2025
The $657 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $43.34 · 2024: $568 · 2025: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,225.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $323.26 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $163.76 | 2019-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $118.38 | 2024-2025 | Evenity, Krystexxa, Prolia |
| Lilly USA, LLC | $97.33 | 2024-2025 | Jardiance, Mounjaro |
| Pfizer INC. | $95.11 | 2025 | |
| Astellas Pharma US INC | $86.36 | 2024-2025 | Veozah |
| Aerin Medical INC. | $59.35 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.04 | 2025 | Jardiance |
| Radius Health, INC. | $51.65 | 2019-2024 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $46.53 | 2024-2025 | Breztri |
| Merck Sharp & Dohme LLC | $44.54 | 2025 | Gardasil 9, Capvaxive |
| Amphastar Pharmaceuticals, INC. | $39.80 | 2024 | |
| Abbott Laboratories | $32.69 | 2024-2025 | Freestyle Libre 3 |
| Becton, Dickinson and Company | $26.57 | 2020 | |
| Baxter Healthcare | $26.19 | 2025 | Hillrom - Carnation Ambulatory Monitor |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.13 | 2024 | Xifaxan |
| Abbvie INC. | $21.34 | 2025 | |
| Corcept Therapeutics | $19.43 | 2024 | Korlym |
| Medtronic, INC. | $18.18 | 2025 | Minimed 780g |
| Sequel Med Tech, LLC | $18.12 | 2025 | Twiist |
| Tandem Diabetes Care, INC. | $17.61 | 2019 | |
| Seqirus USA INC | $17.46 | 2025 | Fluad, Flucelvax |
| Janssen Pharmaceuticals, INC | $16.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Archana Shetty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.